Premium
Omeprazole in peptic ulcers resistant to histamine H 2 ‐receptor antagonists
Author(s) -
TYTGAT G. N. J.,
LAMERS C. B. H. W.,
HAMEETEMAN W.,
JANSEN J. M. B. J.,
WILSON J. A.
Publication year - 1987
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1987.tb00603.x
Subject(s) - omeprazole , cimetidine , medicine , ranitidine , maintenance therapy , gastroenterology , peptic , histamine h2 receptor , refractory (planetary science) , histamine , maintenance dose , chemotherapy , peptic ulcer , surgery , antagonist , receptor , physics , astrobiology
SUMMARY Eighteen patients with duodenal, gastric or jejunal ulcers, resistant to at least 3 months treatment with histamine H 2 ‐receptor antagonists, singly or in combination with other anti‐ulcer drugs, were treated with 40 mg omeprazole once daily for up to 8 weeks. All ulcers healed, the majority within two weeks. After ulcer healing patients were given maintenance therapy with high doses of cimetidine or ranitidine. Of 15 patients on maintenance therapy with H 2 ‐receptor antagonists, 12 (80%) developed a relapse after a period ranging from 3 to 52 weeks. Two patients were lost to follow‐up. After re‐healing on 40 mg omeprazole, two patients were given 20 mg omeprazole daily as maintenance therapy but relapses occurred again after 14 and 26 weeks respectively. After re‐healing on 40 mg omeprazole, these two patients and one additional patient received maintenance therapy with 40 mg omeprazole daily. At present these three patients have been relapse‐free for periods varying from 16 to 52 weeks. No side effects were registered during treatment with omeprazole. It is therefore concluded that omeprazole is highly effective in healing refractory peptic ulcers and that omeprazole maintenance therapy may be useful for prevention of relapse.